GLP-1 Agonist Program

About Biolingus

Biolingus is pioneering a novel drug delivery platform focused on the sublingual (under-the-tongue) administration of large molecule drugs, including peptides, proteins, and vaccines. Its core technology is designed to protect biologics from degradation in the gut and facilitate absorption directly into the bloodstream via the oral mucosa, potentially eliminating the need for painful and costly injections. The company is advancing a pipeline of internal and partnered programs, targeting significant markets in diabetes, obesity, and immunology. As a private, pre-revenue entity, Biolingus's success hinges on validating its platform in clinical trials and securing strategic partnerships to fund development and commercialization.

Therapeutic Areas

Other Type 2 Diabetes, Obesity Drugs